SRRK vs VRDN
SRRK: Scholar Rock develops myostatin-inhibiting monoclonal antibodies to treat rare neuromuscular diseases like spinal muscular atrophy, with lead candidate apitegromab anticipated for regulatory approval in 2026. VRDN: Viridian is a clinical-stage biopharmaceutical company developing potentially differentiated monoclonal antibody therapies for thyroid eye disease and autoimmune diseases, with lead candidate veligrotug advancing through late-stage trials against Amgen's Tepezza.
Side-by-side fundamentals
| Metric | SRRK | VRDN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $48.30 | $19.17 | |
| Market cap as of 2026-07-23 | $5.9B | $2.1B | |
| PEG as of 2026-07-23 | -0.40 | n/a | |
| Net margin as of 2026-07-23 | -237.0% | -508.5% | SRRK higher |
| Gross margin as of 2026-07-23 | n/a | +2.4% | |
| Operating margin as of 2026-07-23 | -231.8% | -543.9% | SRRK higher |
| ROE as of 2026-07-23 | -162.9% | -60.7% | VRDN higher |
| ROA as of 2026-07-23 | -96.3% | -50.6% | VRDN higher |
| Debt / equity as of 2026-07-23 | 0.71 | 0.14 | VRDN lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +23382.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -2.5% | |
| Beta as of 2026-07-23 | 0.65 | 0.93 | |
| 1-year return as of 2026-07-22 close | +20.8% | +13.0% | SRRK higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.